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Abstract. To define the role of protein kinase C (PKC) 
in oxygen-dependent production of erythropoietin (EPO) 
in the liver, we have determined EPO messenger ribo- 
nucleic acid (mRNA) expression in primary cultures of 
juvenile rat hepatocytes incubated at different oxygen 
tensions in the absence and presence of phorbol esters, 
vasopressin, and structurally different kinase inhibitors. 
Upon reduction of oxygen concentrations from 40% to 
3% EPO mRNA in cultured hepatocytes increased mark- 
edly within 1.25 h, reached maximal values after 2.5 h 
and remained elevated for up to 72 h. Treatment of hepa- 
tocytes during 1.25-5 h of hypoxic exposure with phor- 
bol 12-myristate-13 acetate (PMA) attenuated hypoxia- 
induced EPO mRNA levels dose-dependently by a maxi- 
mum of approximately 50%. This inhibitory effect of 
PMA disappeared upon treatment for more than 5 h and 
was completely lost after incubation for 9 and 18 h in 
the presence of 10 -6 M and 10 -7 M PMA, respectively. 
Phorbol 12,13-dibutyrate and vasopressin also inhibited 
EPO mRNA accumulation, whereas 4 alpha-phorbol 
12,13-didecanoate was ineffective. Western blot analysis 
of PKC isozymes revealed the presence of PKC alpha, 
beta II, delta, epsilon and zeta and provided no evidence 
that the PMA-induced inhibition of EPO expression was 
associated with depletion of any of these isozymes. Con- 
versely, PMA-induced inhibition of EPO mRNA ac- 
cumulation was paralleled by translocation ofPKC alpha 
from cytosol to membranes and the time- and dose-de- 
pendent attenuation of the inhibitory effect of PMA on 
EPO mRNA levels was paralleled by down-regulation f
PKC alpha. A dose-dependent i hibition of EPO mRNA 
formation, independent of effects on total RNA syn- 
thesis, as determined by [3H]uridine incorporation, was 
also found in the presence of the kinase inhibitor stauro- 
sporine (EDso --2 • 10 s M) and three structurally re- 
lated derivatives with increased selectivity for PKC (RO 
317549, EDso --1 • -6 M; RO 318220, EDso - - lX  
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10 -6 M and CGP 41251, EDs0 -4  • 10 .6 M). The mark- 
edly lower potency of the latter three compounds as 
compared to staurosporine suggests that this suppression 
of EPO gene induction was not mediated by inhibition 
of PKC. In summary the data indicate that PKC alpha is 
a negative modulator of EPO gene expression i  hepato- 
cytes. A kinase other than PKC, however, appears to be 
an essential element of hypoxic signalling. 
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Introduction 
Erythropoietin (EPO), the major humoral regulator of 
erythropoiesis,  produced by the liver and kidneys in an 
inverse relation to oxygen availability [30]. The major 
control of oxygen-dependent EPO formation has been 
shown to operate at the level of its messenger ribo- 
nucleic acid (mRNA) [3, 4, 43]. Increases in EPO 
mRNA levels upon hypoxia are at least in part mediated 
by increased transcription of the EPO gene [44]. The 
cellular mechanisms through which changes in oxygen 
availability determine EPO gene expression are in spite 
of several hypotheses [30] largely unknown, as in other 
cases of oxygen-dependent gene control [17]. 
Recent evidence indicates that phospholipid and cal- 
cium-dependent protein kinase (PKC) may play an im- 
portant role in hypoxic signalling in a variety of systems. 
PKC consists of at least eight isozymes, several of which 
are coexpressed" in single cells and unequally distributed 
between cytosol and membranes [1, 37, 48]. In general, 
activation of PKC is associated with increased mem- 
brane binding of the enzyme and a parallel decrease in 
cytosolic activity. Prolonged membrane association may 
initiate proteolytic degradation or "down-regulation", a 
process which affects different PKC isozymes to a dif- 
ferent extent and at different rates [1, 37, 48]. It was 
22 
therefore taken as evidence for a possible role of PKC 
as mediator of hypoxic signal transduction, when a 
translocation of PKC from cytosol to membranes and a 
reduction of its activity was observed in fetal rat brain 
during anoxia [34], and in renal LLCPK1 cells upon hy- 
poxic incubation in vitro [42]. Moreover, hypoxia-me- 
diated impaired differentiation of LLCPK1 cells [41] 
was mimicked upon treatment of normoxic cells with 
phorbol esters [42], known activators of PKC [1, 37, 
48]. In pulmonary artery smooth muscle cells, hypoxia 
is known to induce contraction and proliferation. The 
sustained phase of hypoxia-induced contraction was 
found to be inhibited in the presence of an inhibitor of 
PKC and activation of PKC was found to be a prerequi- 
site for pulmonary artery smooth muscle cells to pro- 
liferate in response to hypoxic exposure in vitro [10]. 
In view of these findings it appears of interest hat 
recent evidence also suggests that PKC may be involved 
in the regulation of oxygen-dependent EPO formation. 
However, since it has so far not been possible to isolate 
the cells physiologically producing EPO in liver and kid- 
neys, these studies have been confined to EPO-produc- 
ing turnout cell lines, and the results obtained with these 
cell lines are inconclusive and have led to controversial 
interpretations. Thus, using the human hepatoma cell 
lines Hep G2 and Hep 3B, which produce EPO in an 
oxygen-dependent fashion [22] and a renal carcinoma 
cell line, which secretes EPO constitutively [24], several 
investigators reported that phorbol esters reduce EPO 
formation [19, 25, 31, 33]. However, in addition, inhibi- 
tors of PKC were found to diminish EPO secretion by 
Hep G2 ceils [31, 33]. Moreover, one group found that 
the reduction of EPO formation upon treatment with 
phorbol esters in Hep G2 cells is due to depletion of 
PKC [31], whereas others did not obtain clear evidence 
that down-regulation of PKC is associated with the inhi- 
bition of EPO formation [33]. Finally, synthetic ana- 
logues of diacylglycerol, the endogenous activator of 
PKC [1, 37, 48] were found to inhibit EPO secretion in 
renal carcinoma cells [25] and Hep 3B cells [19], but 
had no effect on EPO production in Hep G2 cells [33]. 
It is possible that these different results may be due to 
intrinsic properties of the different umour cell lines un- 
der investigation, and overall it remains unclear whether 
activation of PKC inhibits EPO formation, or if con- 
versely, down-regulation and inhibition of PKC reduces 
EPO production under certain conditions. Some investi- 
gators have, however, clearly favoured this latter pos- 
sibility, suggesting that PKC plays an important permiss- 
ive role in the stimulation of EPO production [31]. 
In the present investigation we aimed to clarify the 
role of PKC in EPO formation of cells that are physio- 
logical production sites of the hormone. Since in juven- 
ile rats the liver is the predominant site of EPO forma- 
tion [15], and since hepatocytes have recently been iden- 
tified as the main cellular site of EPO production in the 
liver [32, 45] we have studied EPO production in pri- 
mary cultures of juvenile rat hepatocytes. Recently we 
have shown that steady-state l vels of EPO mRNA in 
isolated hepatocytes increase approximately 15-fold 
after incubation at reduced oxygen tensions for 18 h 
[16]. This indicates that primary cultures of hepatocytes 
can be used to investigate oxygen-dependent control of 
EPO formation in vitro. To define the role of PKC in 
hepatic EPO formation, hepatocytes i olated from juven- 
ile rats were incubated in the present study at varying 
oxygen tensions in the absence and presence of phorbol 
esters, of vasopressin, a known activator of PKC in 
hepatocytes [28] and of seven potential, structurally dif- 
ferent, inhibitors of PKC. Effects on EPO mRNA levels 
were related to changes in total RNA synthesis and com- 
pared with changes in the abundance and distribution of 
different isozymes of PKC. 
Materials and methods 
Animals. Male Sprague Dawley rats age 10-20 days, bred in the 
local animal house were used. 
Liver ceil isolation. Cells were isolated from livers using a two- 
stage in situ perfusion via the portal vein [2] in a non-recirculating 
system. The basic perfusion medium consisted of Hanks buffered 
salt solution (HBSS: 137 mM NaC1, 3.7 mM KC1, 0.4 mM 
KHzP04, 0.3 mM Na2HPO4,  mM NaHCO3, 5.5 mM glucose) and 
was supplemented with 10 mM 4(2-hydroxyethyl)-l-piperazine- 
ethane sulphonic acid (HEPES), 0.5 mM ethyleneglycol- 
bis(aminoethylether)tetraacetate (EGTA) (medium 1) or with 10 
mM HEPES, 5ram CaClz, 0.1 mg/ml collagenase (0.287 U/rag) 
(medium 2). After cannulation of the portal vein, livers were 
flushed with I ml sodium heparin (1000 U/ml), then perfused with 
medium 1for 5 rain at a rate of 4.5 rot/rain and subsequently with 
medium 2 for 8 rain at a rate of 3.8 ml/min. Perfusion media were 
preoxygenated and prewarmed to37~ After excision livers were 
immediately placed in ice-cold HBSS and cells were gently liber- 
ated into the buffer after opening of the liver capsule. The suspen- 
sion was cleared of the connective tissue framework and remaining 
clumps of tissue by filtration through a 50 gm nylon sieve. 
Cell culture. Hepatocytes were preferentially sedimented by centri- 
fngation at 80 g for 3 min and washed thrice in ice-cold HBSS. 
Cell viability as assessed by the trypan blue exclusion criterion 
was always greater than 85%. Cells were suspended in minimal 
essential medium, supplemented with 10% fetal bovine serum, 
glutamine (2 raM), penicillin (50U/m1), streptomycin sulphate 
(50 I~g/ml), insulin (10 gg/ml) and hydrocortisone (2 gg/ml) and 
were routinely plated at a density of 8-11 • 104 cells/cm 2 in 175- 
cm 2 dishes. After 4 h incubation at 40% 02/5% COz/55% N2, to 
allow cell attachment, the culture medium was removed together 
with the majority of non-attached cells, the percentage of which 
was consistently ess than 10%. and cultures were refed the same 
medium without serum supplementation. For studies of the time 
course of changes in EPO mRNA levels subsequent incubation 
was carried out for 1.25-72 h at 3% or 40% Oz/5% CO2/balance 
N2 in waterjacketed incubators tModel 3319 and 3336. Forma 
Scientific, Marietta, Ohio. USA). Cells isolated from two animals 
were generally combined and yielded 12-16 dishes, from which 
at least I dish of cells without treatment was kept at 3% O2 or 
40% O2 to provide internal controls. For pharmacological studies 
cells were generally incubated for 1.25-18 h. Stock solutions of 
pharmacological gents were prepared in dimethylsulphoxide 
(DMSO) and added to the serum-free medium after the preincuba- 
tion phase (final concentration ofDMSO 0.1%). 
In order to test the effect of pharmacological gents on the 
stability of EPO mRNA, hepatocytes were incubated at 3% Oz for 
2.5 h in the absence of drugs to induce accumulation of EPO 
mRNA and thereafter xposed to 40% O2for 1.25 h in the presence 
of agents. 
Measurement of EPO mRNA. Cells were harvested with trypsin 
ethylenediaminetetraacetate (EDTA), snap frozen in liquid nitro- 
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gen and stored at -70~ prior to RNA extraction. RNA was pre- 
pared using an acid/guanidinium thiocyanate/phenol/chloroform 
extraction method [8] and was assayed by RNAse protection as 
described [38]. RNA probes were continuously abelled with [a- 
32p]GTP (1.5 X 10 ~3 Bq/mmol) by SP6 polymerase, using a gen- 
omic rat EPO deoxyribonucleic a id (DNA) template, which com- 
prised a Pst I-Sac I fragment, containing 132 bp of exon V and 
approximately 300bp of the adjoining intron. 100-150 txg total 
RNA was hybridized with 0.25 to 0.5• cpm [(4.17- 
8.34) • 103 Bq] radiolabelled EPO probe in 80% formamide, 40 
mM 1,4-piperazine-diethanesulphonic ac d(PIPES, pH 6.4), 400 
mM NaC1, 1 mM EDTA at 60~ overnight and RNAse digestion 
was performed at 20~ for 30 min. Protected fragments were sub- 
jected to denaturing polyacrylamide gel electrophoresis (PAGE) 
and quantified by measuring radioactivity of excised portions of 
the dried gel in liquid scintillant (1500 Tri-Carb liquid Scintillation 
Analyzer, Packard Instrument Company, Downers Grove, Ill., 
USA). Equivalent amounts of yeast ransfer RNA (tRNA) were run 
in each assay to assess background radioactivity. After background 
subtraction the radioactivity of each protected EPO mRNA frag- 
ment was divided by the quantity of total RNA analysed and ex- 
pressed relative to an external standard, as described [15] con- 
sisting of 1 ~tg pooled RNA extracted from kidneys of severly 
anaemic adult rats, which was coanalysed with each gel and as- 
signed an arbitrary value of 1. 
Measurement of total RNA synthesis. [3H]Uridine incorporation 
into trichloroaceticacid (TCA)-insoluble material was used as a 
measure of total RNA synthesis as described [50] in cultures that 
were incubated under conditions identical to those used for 
measurement of EPO mRNA, except that 9.6-cm 2 dishes were 
used. In brief, 3.7 • 103 Bq [5-3H]uridlne (1.04• 10 ~2 Bq retool) 
was added to the dishes for 2.5 h of incubation at 3% or 40% 
oxygen. At the end of the incubation period the culture dishes were 
immediately transferred toa cold room. The cells were rinsed with 
1 ml ice-cold PBS, and the cell layers were covered with 3 ml ice- 
cold TCA (10%) to extract TCA-soluble nucleotides in situ at 4~ 
for 50 rain. After washing the cells three times with cold TCA 
(10%), they were dried at room temperature and digested in 1 ml 
of  I N KOH. Radioactivity was counted in liquid scintillant after 
neutralization with 1 N HCL. 
Immunodetection ofPKC isozymes. Cytosolic and membrane frac- 
tions were prepared from hepatocytes incubated in the absence or 
presence of PMA (10-8-10 -6 M) for 2.5 or 18 h at 3% or 40% 
oxygen. At the end of incubation culture dishes were placed on 
ice, cells were washed thrice with TBS (4~ supplemented with 
leupeptin (10 pg/ml) and aprotinin (2 Ixg/ml), and scraped into 
1 ml of sonication buffer (20 mM TRIS-HC1, 2 mM EGTA, 2 mM 
EDTA, 6 mM beta-mercaptoethanol, 2 Ixg/ml aprotinin and 10 Ixg/ 
ml leupeptin). Cell suspensions were sonicated (3 bursts of 75 W) 
and extracts were spun at 100,000 g for 1 h, yielding the cytosolic 
superuatant. Pellets were resuspended in sonication buffer sup- 
plemented with 1% NP 40 and spun again at 100,000 g for 1 h to 
yield the membrane fraction. 
Protein concentration in cytosolic and membrane fractions was 
determined by the Bradford method [6] and samples of 300 gg 
protein were subjected to SDS-PAGE and thereafter t ansferred 
onto nitrocellulose filters. After being washed, filters were incu- 
bated with a monoclonal antibody against he alpha isozyme, or 
polyclonal antibodies against he beta I, beta II, gamma, delta, 
epsllon, zeta and eta isozymes of PKC exactly as described [5]. 
Binding was detected by autoradiography after incubation with 
~25I-labelled antibodies against mouse gamma-globulin a d autora- 
diograms were evaluated by laser densitometry (elscript 400, 
Hirschmann, Unterhaching, Germany). 
Statistics. Student's paired t-test was used for comparison of EPO 
mRNA levels in pharmacologically treated hepatocytes with those 
in control dishes obtained from the same cell preparation, which 
were incubated and analysed in parallel; P < 0.05 was considered 
significant. 
Agents. Phorbol 12-myristate (PMA), phorbol 12,13 dibutyrate 
(PDBu), 4-a-phorbol 12,13 didecanoate (a-PDD), protease inhibi- 
tors, staurosporine, dioctanoylglycerol (DOG) and oleoyl-acetyl- 
glycerol (OAG) and vasopressin were from Sigma. NP 40 was 
from Calbiochem, collagenase was from Boehringer Mannheim, 
cell culture medium and fetal bovine serum were from Gibco BRL. 
Radiochemicals were purchased from Amersham. A monoclonal 
antibody against PKC alpha was from Amersham, a polyclonal 
antibody against PKC gamma from Seikagaku Kogyo (Tokyo, Ja- 
pan). Polyclonal antibodies against PKC beta I and beta IX were 
generous gifts from Dr. S. Jaken (Lake Placid, NY, USA) and 
polyclonal antibodies against other PKC isozymes were prepared 
as described [29]. 1-(5-Isoquinolinesulphonyl)-2-methylpiperazine 
(H 7), N-[2-(methylamino)ethyl]-5-isoquinoline-sulphonamide (H 
8) and N-(2-aminoethyl)-5-isoquinolinesulphonamide (H 9) were 
from Research Biochemicals. RO 31 8220, RO 31 7549 and CGP 
41251 were gifts from Roche Products Limited, UK, and Ciba 
Geigy, Switzerland, respectively. A partial rat EPO DNA probe 
was kindly provided by Dr. E J. Ratcliffe, Oxford, UK. 
Results 
EPO mRNA levels in isolated hepatocytes 
incubated at different oxygen tensions 
Figure 1 shows the time course of  EPO mRNA levels 
in primary cultures of  hepatocytes. Although cells were 
isolated from normoxic animals EPO mRNA was readily 
detectable after cell isolation, which is in accordance 
with previous data from in vivo studies [15]. When cells 
were preincubated at 20% oxygen for 4 h, as in previous 
experiments [16] average concentrations of EPO mRNA 
did not change significantly (not shown), but when 
preincubation of  cells was performed at 40% oxygen, 
EPO mRNA levels after 4 h were significantly lower 
than immediately after isolation, and in many experi- 
ments became undetectable. Reducing the oxygen ten- 
sion in the incubator to 3% after the end of the preincu- 
bation period resulted in a marked increase of  EPO 
mRNA levels within 2.5 h. Despite continued hypoxic 
exposure, a reduction of  EPO mRNA levels occurred 
between 5 and 9 h, before the concentration of  EPO 
mRNA remained fairly constant. At 40% oxygen EPO 
mRNA levels remained low and a marked difference be- 
tween incubation at 40% and 3% oxygen persisted dur- 
ing the period investigated. 
For subsequent pharmacological studies hepatocytes 
were always preincubated for 4 h at 40% oxygen and 
thereafter exposed to 3% or 40% oxygen in the absence 
or presence of  agents. 
Effect of phorbol esters on EPO mRNA accumulation 
and total RNA synthesis 
The effect of  phorbol esters on EPO mRNA accumu- 
lation in rat hepatocytes incubated at 3% oxygen for 
1 .25-18  h is shown in Fig. 2; Fig. 2 A is the autoradio- 
gram of an RNAse protection assay from a single experi- 
ment with PMA, and Fig. 2 B, C illustrates the quantita- 
tive analysis, derived from the determination of  the ra- 
dioactivity of  protected fragments in 4 -10  independent 
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Fig. 1. Time course of erythropoietin messenger ribo- 
nucleic acid (EPO mRNA) levels in isolated rat hepato- 
cytes. After isolation cells were preincnbated for 4 h 
( -4  to 0 h) at 40% 02 in medium supplemented with 
10% fetal calf serum (FCS) to allow cell attachment and 
thereafter incubated in serum-free medium at 40% 02 
(O) or 3% 02 (0) for up to 72 h. EPO mRNA was 
measured by RNAse protection using a 32P-labelled 
RNA probe and quantified by determination f the ra- 
dioactivity of protected fragments. Values are expressed 
relative to an external standard (aliquot of pooled renal 
RNA) that was coanalysed on each gel and assigned an 
arbitrary value of i (mean _+ SEM, n = 12) 
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Fig. 2A-C. Effect of phorbol esters on EPO 
mRNA accumulation i  isolated hepatocytes in- 
cubated at 3% 02 for 1.25-18 h. A The autora- 
diograph of an RNAse protection assay of a sin- 
gle experiment with phorbol 12-myristate-13 
acetate (PMA), using t l0 gg of total RNA from 
cells under each condition. B, C Quantitative 
analysis, derived from measurement of the radio- 
activity of protected fragments i  RNAse protec- 
tion assays of independent experiments in which 
cells were treated with different concentrations 
of PMA, phorbol 12,13 dibutyrate (PDBu) and 
4a-phorbol 12,13 didecanoate (PDD) for 2.5 h 
(B) or with two different concentrations of PMA 
for 1.25-18 h (C). Values are related to controls 
incubated in parallel at 3% 02 in the absence of 
phorbol esters and are given as mean _+ SEM, 
n = 4 -5  except values for 10 .6 M and 10 .7 M 
PMA in (B) (n = 10). EPO mRNA values were 
significantly lower than in control dishes follow- 
ing treatment for 2.5 h with 10-8, 10 .7 or 
10 .6 M PMA and 10 .6 M PDBu and also follow- 
ing treatment with 10-7 M PMA for t.25 or 9 h 
experiments with PMA, PDBu and alpha PDD. Treat- 
ment with PMA did not affect the yield of  total RNA 
extractable from hepatocytes (not shown), but resulted 
in a dose- and time-dependent reduction of  the level of  
EPO mRNA per I-tg total RNA. Upon incubation for 
2.5 h in the presence of PMA, reduction of  EPO mRNA 
levels was maximal with 10 .7 M PMA (on average 
56%) and was less pronounced with a tenfold higher 
concentration (average reduction 33%) (Fig. 2A ,  B). 
The reduction in EPO mRNA levels was already appar- 
ent after 1.25 h of  incubation, but was reversed com- 
pletely upon incubation in the presence of the phorbol 
ester for more than 2.5 h. This loss of  efficacy occured 
more rapidly with 10 -6 M PMA than with 10 -7 M PMA. 
Thus average EPO mRNA levels in cells treated with 
10 -7 M PMA remained at about 50% of control values 
after 5 h and were still significantly reduced after 9 h, 
whereas EPO mRNA concentrations after this time peri- 
od were even slightly higher than in control cultures 
upon treatment with a tenfold higher dose (Fig. 2 C). 
PDBu mimicked the effect of  PMA, although with 
less potency, while the biologically inactive phorbol es- 
ter alpha PDD [47] did not affect EPO mRNA concen- 
trations (Fig. 2 B). Phorbol esters did not increase EPO 
mRNA concentrations in hepatocytes incubated at 40% 
oxygen for 2.5 h (not shown). 
In agreement with previous results [16] total RNA 
synthesis in hepatocytes, as determined by [3H]uridine 
Table 1. Effect of phorbol 12-myristate-13 acetate (PMA) and va- 
sopressin on total RNA synthesis 
Experimental condition [3H]Uridine 
trichloroacetic acid 
(TCA)-insoluble 
counts 
(cpm per dish) 
40% O2 Control 2099 _+ 58 
3% O2 Control 960 + 19 
3% O2 PMA (10 8 M) 957 + 73 
3% O2 PMA (10 -7 M) 861 + 45 
3% O2 PMA (10 -6 M) 924 _+ 33 
3% 02 Vasopressin (10 -7 M) 933 _+ 52 
Values are mean + SEM, n = 3-5. Following 4 h preincubation 
at 40% O2 cells were incubated for2.5 h in the presence of agents 
and 3.7 • 103 Bq [3H]uridine per dish 
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Fig.3. Effect of vasopressin on EPO mRNA levels in isolated 
hepatocytes incubated at 3% 02 for 2.5 h. Values are related to 
controls incubated in parallel at 3% O2 in the absence of vasopres- 
sin (mean +_ SEM, n = 3). With 10 .8 and 10-TM vasopressin 
EPO mRNA levels were significantly lower than in controls 
incorporation, was approximately 50% lower at 3% oxy- 
gen as compared to 40% oxygen (Table 1). The inhibi- 
tory effect of phorbol esters on EPO mRNA accumu- 
lation was specific in so far as total RNA synthesis in 
the presence of PMA was unchanged or only slightly 
affected (Table 1). 
Effect of vasopressin and synthetic diacylglycerols 
on EPO mRNA accumulation 
In order to stimulate PKC through activation of phos- 
pholipase C hepatocytes were incubated for 2.5 h at 3% 
oxygen in the presence of vasopressin. As shown in 
Fig. 3, vasopressin reduced EPO mRNA levels in a 
dose-dependent fashion, without affecting total RNA 
synthesis (Table 1). Treatment with OAG and DOG 
(10-4-10 -7 M) for 2.5 h had no consistent effect on 
either basal or hypoxia-induced EPO mRNA levels (not 
shown), 
Immunological quantitation of PKC isozymes 
To relate dose- and time-dependent changes in EPO 
mRNA accumulation i the presence of PMA to changes 
Fig. 4. Western blots f PKC alpha, zeta and epsilon, performed 
with cytosolic (C) or membrane-bound (M) protein of hepatocytes 
incubated at 3% 02 for 2.5 or 18 h in the absence or presence of 
PMA. Arrows on the left correspond to molecular sizemarkers 
(upper: 94kDa, lower: 68 kDa). Autoradiograms are shown f r 
one of three analyses with independent cell preparations, which 
provided similar esults. For semiquantification autoradiograms 
were analysed by laser densitometry. Relative densitometric values 
for PKC alpha are given in Fig. 5. The slight increase in both the 
cytoplasmic and membrane bound PKC alpha band of untreated 
cells after 18 h as compared to 2.5 h on the illustrated autoradio- 
gram was not reproducible in two other experiments. The immuno- 
reactivity of PKC zeta showed noconsistent change under PMA 
treatment. PKC epsilon in the cytosol decreased an  in the mem- 
branes increased slightly under PMA treatment; when related to 
the signal in the membranes of untreated cells the intensities were: 
0.75 (C, 2.5 h) and 0.25 (C, 18 h) in untreated cells and 0.22 (C, 
2.5 h), 1.22 (M, 2.5 h), 0.11 (C, 18h) and 1.25 (M, 18h) in cells 
treated with 10 -6 M PMA 
in the subcellular distribution of PKC isozymes, cyto- 
solic and membrane fractions were prepared from hepa- 
tocytes that were incubated at 3% or 40% oxygen for 
2.5 or 18 h in parallel to cultures used for EPO mRNA 
measurements. Using Western blot analysis, PKC iso- 
zymes alpha, beta II, delta, epsilon and zeta, but not beta  
I, eta or gamma were detected in hepatocytes. 
Neither in the absence nor presence of PMA was any 
consistent difference found in the abundance or subcel- 
lular distribution of PKC isozymes between cells incu- 
bated at 3 or 40% oxygen (not shown). 
In the absence of PMA PKC alpha and beta II were 
predominantly found in the cytosolic fraction, while 
PKC delta, epsilon and zeta were predominantly mem- 
brane bound. Following treatment with PMA, no 
changes in the immunoreactivity of PKC beta II and zeta 
(Fig. 4) became apparent. In contrast, PKC a (Figs. 4, 
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Fig. 5. Densitometric analysis of PKC alpha immunoreactivity in 
Western blots of three independent experiments performed with 
cytosolic (O) or membrane-bound (0) protein of hepatocytes in- 
cubated at 3% Oz for 2.5 or 18 h in the absence or presence of
PMA. Values are expressed asa percentage of the intensity inthe 
membranes of untreated cells (mean + SEM) 
5), epsilon (Fig. 4) and delta were translocated from 
cytosol to membranes, although at different concen- 
trations of phorbol ester and to a different extent, which 
is in accordance with a previous tudy in rat hepatocytes 
[39]. As illustrated in the autoradiogram of a single 
experiment (Fig. 4) and by the densitometric analysis of 
three independent experiments (Fig. 5), translocation of
PKC alpha and a commencing reduction of the overall 
abundance was found already after 2.5 h incubation with 
no less than 10 -7 M PMA. After 18 h incubation with 
no less than 10-7M PMA almost complete down-re- 
gulation had occurred (Figs. 4, 5). PKC e showed 
slight depletion of the cytosolic fraction with no less 
than 10 -7 M PMA after both 2.5 and 18 h, but no down- 
regulation of the membrane-bound form (Fig. 4). A 
slight down-regulation f PKC delta was only seen at a 
concentration f PMA as high as 10-6M (not shown). 
Effects of kinase inhibitors on EPO mRNA levels and 
total RNA synthesis 
In an attempt to investigate hypoxia-induced EPO 
mRNA accumulation i  the presence of reduced activity 
of PKC, cells exposed to 3% oxygen for 2.5 h were 
treated with staurosporine [40], the staurosporine d riva- 
tives CGP 41251 [35], RO 318220, RO 317549 [9, 12] 
and the isoquinolinesulphonamides H7, H8 and H9 [26]. 
In order to assess unspecific alterations of RNA syn- 
thesis, [3H]uridine incorporation was measured in paral- 
lel. As shown in Fig. 6, all kinase inhibitors tested led 
to a dose-dependent at enuation of EPO mRNA levels 
(closed symbols). Treatment with CGP 41251 reduced 
EPO mRNA levels (EDso -- 4 • 10 -6 M) without having 
a significant effect on total RNA synthesis (open sym- 
bols) (Fig. 6 B). Treatment with the other kinase inhi- 
bitors affected not only EPO mRNA levels but also 
resulted in marked reduction of total RNA synthesis, 
albeit with lower potency in the case of staurospo- 
rine (Fig. 6 A), RO 318220 and RO 317549 (Fig. 6 D) 
(EDso -- 2 X 10 -s M vs -- 6 • 10 -7 M, --1 • 10 -6 M vs 
5XI0-6M and -- 1• vs -- 6• for 
inhibition of EPO mRNA accumulation and total RNA 
synthesis, respectively). H7, H8 and H9 inhibited EPO 
mRNA accumulation with about the same potency as 
total RNA synthesis (Fig. 6 C). 
Effect of PMA vasopressin and kinase inhibitors 
on the decay of EPO mRNA 
after hypoxic stimulation of hepatocytes 
To assess indirectly if PMA and the kinase inhibitors 
reduce steady-state levels of EPO mRNA under hypoxia 
through inhibition of de novo synthesis of EPO mRNA 
or increased mRNA metabolism, hepatocytes were in- 
cubated at 3% oxygen in the absence of drugs to in- 
duce accumulation f EPO mRNA, and PMA (10 -7 M), 
vasopressin (10-?M), staurospofine (10-SM), RO 
318220 (10 .6 M), RO 317549 (10 -6 M) and CGP 41251 
(10 5 M) were then added to cultures during a further 
incubation for 1.25 h at 40% oxygen. Figure 7 illustrates 
that EPO mRNA decreased by about two-thirds after 
1.25 h and that this decay was not enhanced by any of 
the substances tested. 
Discussion 
Hepatocytes have recently been identified as the pre- 
dominant site of oxygen-dependent EPO production in 
rats during the early postnatal period [15, 32, 45], and 
we have previously observed that the ability of hepato- 
cytes to modulate EPO production in an oxygen-depen- 
dent fashion is maintained after isolation of the cells 
[16]. Extending these observations, tudies of the time 
course of EPO mRNA levels in isolated hepatocytes 
(Fig. 1) show that oxygen-dependent differences in EPO 
mRNA can be found for at least 72 h of primary culture 
under serum-free conditions when cells are incubated at 
either low or high oxygen pressures. As in the liver in 
vivo [49] and in cultured human hepatoma cells [18], 
the increase in EPO mRNA levels of isolated hepato- 
cytes upon continuously reduced oxygen supply is in 
part only transient (Fig. 1). Although in cultured hepato- 
cytes maximal concentrations of EPO mRNA were 
reached somewhat earlier than following the onset of 
hypoxia in vivo [49], the decline in EPO mRNA of iso- 
lated cells after 2.5-5 h of incubation suggests that the 
down-regulation f EPO production in vivo is not pri- 
o 
"6 
120 
100 
50 
9 [] 
9 d 
.E  -5 ~ 12o 
8 < Z 
< tr 100 
o 
u. I  
50 
staurosporine 
A 
0.. 
'\Q 
~ 
CGP 41251 B 
O- - -  9  
- -o  
= I 
10'-10 10-9 10.8 10.7 10-6 
H8 (A,~} XN b 
H9 (,,D) ~,  
10-6 10.5 10-4 
i i r i i 
10-9 10-8 10-7 10-6 10-5 
, , i = 
10'-9 10-8 10.7 -10-6 10.5 
inhibitor concentration (M) 
27 
Fig. 6A-D. Effect of kinase inhibitors on 
EPO mRNA levels and total RNA synthesis 
in isolated hepatocytes incubated at 3% oxy- 
gen for 2.5 h. Values are related to controls 
from the same cell preparation, i cubated in 
parallel at 3% 02 in the absence of agents. 
EPO mRNA was quantified by RNAse pro- 
tection and [3H]uridine incorporation i to 
tfichloroacetic-acid-(TCA)-insoluble mat rial 
was used as a measure of total RNA syn- 
thesis. Values are mean • n = 5. 
EPO mRNA levels were significantly lower 
than in controls following treatment with 
/>10 -8 M staurosporine, />10 6 M CGP 
41251, 10 -4 M H 7, H 8 or H 9 {where H 7 
is 1-(5-isoquinolinesulphonyl)-2-methyl- 
piperazine, H 8 is N-[2-(methylamino)ethyl)- 
5-isoquinoline-sulphonamide an  H 9 is N- 
(2-aminoethyl)-5-isoquinoline- 
sulphonamide} and --> 10 -6 M RO 31 7549 or 
RO 31 8220. Total RNA synthesis was signif- 
icantly lower than in controls following treat- 
ment with 10 -6 M staurosporine, 10-4 M 
H 7, H 8 or H 9, 10 -5 M RO 31 7549 and 
t0  6M RO 31 8220 
marily due to changes in peripheral oxygen availability 
[30], but rather depends on cellular mechanisms. With 
respect o further study of the oxygen dependent signal 
transduction that controls EPO formation, the kinetics of 
EPO mRNA levels in isolated hepatocytes indicate that 
short-term exposure of the cells to reduced oxygen ten- 
sions provides a suitable model system. 
Using this system to test a role of PKC in hepatic 
EPO formation we found evidence for a significant ef- 
fect of this kinase. Two active phorbol esters, PMA and 
PDBu, and vasopressin, a physiological activator of 
PKC in hepatocytes [28], were found to inhibit hypoxia- 
induced EPO mRNA accumulation (Figs. 2, 3). This 
suppression appeared to be due to a reduction of EPO 
mRNA synthesis rather than a reduction of mRNA stab- 
ility (Fig. 7), and it was specific in so far as total RNA 
synthesis, as determined by uridine incorporation rates, 
remained almost unaffected (Table 1). The threshold 
dose of PMA required to reduce EPO mRNA levels was 
low (10-9-10 -s M) (Fig. 2 B) and inhibition was appar- 
ent already after 1.25 h of treatment (Fig. 2 C). 
After 2.5 h, the overall abundance of each of five 
PKC isozymes detected in hepatocytes, as well as their 
distribution between soluble and particulate fractions, 
was not affected following incubation with 10 .8 M PMA 
(Fig. 4). This provides strong evidence, that the inhibi- 
tory effect of phorbol ester on EPO formation was not 
associated with down-regulation of any of the detectable 
isozymes of PKC. Moreover, indirect evidence suggests 
that activation of PKC alpha mediates the PMA-induced 
inhibition of EPO expression, and that down-regulation 
of this isozyme antagonizes this inhibition. Thus follow- 
ing treatment with no less than 10 -7 M PMA for 2.5 h, 
a translocation of PKC alpha from cytosol to membranes 
was observed, indicative of strong activation, and, with 
increasing doses, a progressive reduction in the overall 
abundance, presumably reflecting reduced activity. It is 
conceivable that a combination of these two effects re- 
sulted in a maximal inhibition of EPO expression at a 
dose of 10 -7 M PMA and that further down-regulation 
of PKC alpha with further increases in the concentration 
of PMA is responsible for less efficient inhibition 
(Fig. 2 B). In addition, the inhibition of hypoxia-induced 
EPO mRNA levels by PMA was not persistent and was 
completely reversed after 5 -9  h and after 9 -18  h of 
treatment with 10 .6 and 10-7M PMA, respectively 
(Fig. 2 C), and this loss of effect was paralleled by an 
almost complete down-regulation of PKC alpha after 
18 h (Figs. 4, 5). 
Based on the comparison between time- and dose- 
dependent changes in PKC immunoreactivity and inhi- 
bition of EPO mRNA accumulation upon exposure to 
PMA, isozymes other than PKC alpha are less likely to 
mediate the effect of phorbol ester on EPO formation. 
In the case of PKC beta II and zeta neither translocation 
nor down-regulation were observed (Fig. 4). Cytosolic 
PKC epsilon translocated to membranes, but this iso- 
zyme was not down-regulated at any concentration of 
PMA. PKC delta exhibited a slight down-regulation 
after 2.5 h of treatment with 10 .6 M PMA, but this re- 
mained incomplete after 18 h and, moreover, treatment 
for 18 h with 10 .7 M PMA did neither induce transloca- 
tion, nor down-regulation of this subtype. In view of 
the fact that an increasing number of PKC isozymes is 
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Fig. 7A, B. Effect of substances found to reduce steady- 
state levels of EPO mRNA under hypoxic exposure of
hepatocytes (see Figs. 2, 3, 6) on the decay of EPO mRNA 
after hypoxic exposure. Following preincubation at 40% 02 
for 4 h hepatocytes were first incubated at3% O2 for 2.5 h 
in the absence ofdrugs and agents were then added uring 
subsequent i cubation at40% O2 for 2.5 h before cells were 
harvested for isolation of total RNA. A Autoradiograph of 
an RNAse protection assay of EPO mRNA from cells of a 
single xperiment; B quantitative analysis of three indepen- 
dent experiments (mean _+ SEM) 
currently being recognized, we cannot exclude that ad- 
ditional, yet undetected, isozymes may also influence 
EPO expression. We can also not exclude with certainty 
that mechanisms other than stimulation and down-regu- 
lation of PKC activity contribute to the time- and dose- 
dependent effects of phorbol esters. However, the results 
obtained so far appear entirely compatible with an in- 
hibitory effect of the activation of PKC alpha on EPO 
mRNA accumulation i  hepatocytes. 
A low efficacy of synthetic diacylglyerol analogues 
in inducing PKC-mediated reactions in hepatocytes has 
previously been observed [11, 27], possibly due to high 
rates of metabolism of these substances [14]. Thus the 
failure to lower EPO mRNA levels with DOG or OAG 
appears no compelling argument against PKC-mediated 
reduction of EPO gene expression. Following the inter- 
pretation that PKC inhibits EPO mRNA accumulation 
the question arises as to whether basal activity of PKC 
in hepatocytes may lead to a tonic suppression of EPO 
formation. Our results uggest, indirectly, hat this is not 
the case. Thus EPO mRNA concentrations after down- 
regulation of PKC alpha, i. e. after 18 h of hypoxic expo- 
sure (Fig. 2 C) were only marginally higher than in un- 
treated controls. Moreover, in accordance with this, but 
in contrast o previous observations in LLCPK I cells 
[42], we did not obtain evidence that hypoxia per se has 
profound effects on the activity of PKC in hepatocytes; 
the immunoreactivity of PKC isozymes in soluble and 
particulate fractions of hepatocytes xposed to 3% and 
40% oxygen was identical. 
A more direct way to study EPO mRNA formation 
in the absence of PKC activity would be to use inhibitors 
of this enzyme. In fact seven different agents known to 
inhibit PKC activity in other systems were found to re- 
duce EPO mRNA expression in isolated hepatocytes 
(Fig. 6). However, in case of H7, H8 and H9 the dose/ 
response curves for inhibition of EPO mRNA accumu- 
lation and inhibition of total RNA synthesis were almost 
identical, indicating that hese substances did not specifi- 
cally interfere with EPO mRNA expression (Fig. 6 C). 
In contrast, markedly lower concentrations of staurospo- 
rine were required for inhibition of EPO mRNA ac- 
cumulation than for reduction of total RNA synthesis 
(Fig. 6 A). Also RO 317549 and RO 318220 exhibited 
some, albeit less, pronounced selectivity for inhibition 
of EPO mRNA expression as compared to total RNA 
synthesis (Fig. 6 D), and an incomplete suppression of 
hypoxia-induced EPO mRNA levels was also found with 
CGP 41251 (Fig. 6 B). 
At first glance this inhibition of EPO mRNA ex- 
pression with potential inhibitors of PKC seems to con- 
tradict he conclusion derived from the experiments with 
phorbol esters, that PKC is a negative modulator of EPO 
production. However, none of these inhibitors is specific 
for PKC, presumably because all are thought to interfere 
with the catalytic domain of PKC, which shows hom- 
ology with that of other kinases [1, 40]. Thus staurospor- 
ine is known to inhibit not only PKC but also, for ex- 
ample, cyclic-nucleotide dependent kinases, tyrosine ki- 
nase, Ca2+-calmodulin-dependent kinase [1, 40] and 
29 
p34Cdc2-1ike inases [20]. The three structurally different 
derivatives of staur0sporine, RO 317549, RO 318220 [9, 
12] and CGP 41251 [35] exhibit increased selectivity for 
PKC, but were also shown previously to inhibit cyclic- 
nucleotide-dependent ki ases [9, 26, 35] or tyrosine kin- 
ase [7, 35]. In fact, a comparison of the concentrations 
of the various inhibitors required to suppress EPO gene 
induction with those concentrations required to suppress 
PKC-mediated reactions in other systems uggests that 
the inhibitory effect on EPO gene expression is not me- 
diated by inhibition of PKC. Thus others have pre- 
viously reported that staurosporine and RO 318220 are 
equally potent and that RO 317549 is five- to tenfold 
less efficient in inhibiting cellular eactions mediated by 
PKC, such as PMA-induced P47 phosphorylation i
platelets [9] or PMA-induced prostaglandin Ez (PGE2) 
formation in liver macrophages [12]. The concentration 
of staurosporine that inhibits EPO mRNA expression is 
in the same range as that required to inhibit PKC-me- 
diated reactions, but both RO 317549 and RO 318220 
were 50-fold less potent han staurosporine in inhibiting 
EPO mRNA accumulation. Second, CGP 41251 was re- 
ported to be 3 -9  times less potent han staurosporine in 
inhibiting the PKC-mediated H202 release from human 
monocytes, and in inhibiting proliferation of different 
cell lines [35]. At doses required for these inhibitory 
effects, CGP 41252 did, however, only marginally affect 
EPO gene expression, and considering half-maximal in- 
hibition of EPO mRNA accumulation CGP 41252 was 
approximately 200-fold less efficient han staurosporine. 
It appears likely therefore that the effect of these kinase 
inhibitors is not due to inhibition of PKC, but that an- 
other, as yet undefined, kinase activity is an important 
element in the signal transduction that determines oxy- 
gen-dependent control of hepatic EPO mRNA levels. We 
have previously shown that addition of cAMP and 
cGMP to hepatocytes incubated at ambient oxygen 
pressure does not increase EPO mRNA levels, indicating 
that cAMP- and cGMP-dependent kinases do not di- 
rectly mediate hypoxic signalling in these cells [16], but 
this does not exclude a possible permissive role. More- 
over, it is important in this respect, that a haem protein 
was suggested to operate as oxygen sensor in the control 
of EPO formation [23] and that in Rhizobium meliloti an 
oxygen-sensing haem protein with kinase activity was 
identified [21]. Under hypoxic conditions this FixL pro- 
tein of R. meliloti nitiates expression of genes required 
for nitrogen fixation (Nif and fix genes) by protein phos- 
phorylation [36]. It is tempting to speculate that a similar 
mechanism ay be involved in the stimulation of EPO 
gene transcription. 
A comparison of our present results in hepatocytes 
with previous tudies on the role of PKC for EPO prod- 
uction in tumour cells [25, 31, 33] suggests that the in- 
hibitory effect of both phorbol ester and kinase inhibitors 
is retained in transformed liver and kidney cells, but sig- 
nificant differences are obvious. First, in contrast to re- 
sults reported by Jelkmann et al. [31] for Hep G2 cells 
we did not find that the reduction of EPO formation 
upon treatment with phorbol esters in hepatocytes is due 
to depletion of PKC, but rather obtained evidence that 
the activation of PKC inhibits EPO production. Second, 
in hepatoma cells EPO production can be fully blunted 
by phorbol esters [19, 31, 33], whereas in hepatocytes 
phorbol esters only attenuated EPO gene expression. Fi- 
nally, the inhibitory effect of phorbol esters on EPO for- 
mation of hepatoma and renal carcinoma cells was found 
to be long lasting in comparison to the inhibition of EPO 
formation in hepatocytes. Although in hepatoma ceils a 
direct comparison between EPO mRNA expression and 
immunoreactivity of PKC isozymes was not performed, 
one possible xplanation which might in part explain the 
latter two differences i that the time required for down- 
regulation of PKC activity in hepatoma cells is known 
to be unusually long [13] compared with other cells, in- 
cluding hepatocytes [39]. A prolonged activity of PKC 
in hepatoma cells would support our interpretation that 
down-regulation of PKC antagonizes the phorbol ester 
effect on EPO formation. 
In conclusion this study provides evidence that PKC 
alpha inhibits EPO gene expression in hepatocytes. Al- 
though we obtained no evidence that PKC is directly 
involved in hypoxic signalling, it may be an important 
negative modulator of EPO formation in vivo. Serum 
levels of vasopressin, e.g. which is known to induce 
activation of PKC in hepatocytes [28], were found to 
increase in hypoxia-exposed rats [46], and it is conceiv- 
able that such an increase may partially counteract a rise 
in EPO mRNA. 
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